Chan Cheah, MBBS, discusses the investigation of BGB-11417 with or without zanubrutinib in chronic lymphocytic leukemia.
Chan Cheah, MBBS, clinical professor, University of Western Australia (WA), consultant hematologist, lymphoma lead, fellowship program director, Sir Charles Gairdner Hospital, Pathwest Laboratory Medicine WA, Linear Clinical Research and Hollywood Private Hospital, founder, Blood Cancer Research WA, discusses the investigation of BGB-11417 with or without zanubrutinib (Brukinsa) in chronic lymphocytic leukemia (CLL).
In a phase 1 study (NCT04277637), investigators evaluated the safety, tolerability, and maximum tolerated dose of BGB-11417 monotherapy and BGB-11417 in combination with zanubrutinib.
Investigators treated 159 patients, a majority of whom had CLL, Cheah says. Of these patients, 8 were treated with BGB-11417, and 71 patients were received BGB-11417 combination therapy, Cheah notes.
In terms of preliminary efficacy, patients in the monotherapy cohort had an overall response rate (ORR) of 67%, with 33% of responses being complete responses (CR), Cheah explains. In the combination cohort, ORR rates were 95% and 100% in the relapsed/refractory and treatment-naïve cohorts, respectively, Cheah says.
Notably, the combination cohorts had a much shorter duration of follow-up vs the monotherapy cohort, Cheah concludes.